Q Biomed Inc.

83 articles with Q Biomed Inc.

• Q BioMed's Uttroside-B Receives U.S. Patent in Treatment of Liver Cancer

  11/16/2020

  Q BioMed Inc. (OTCQB: QBIO), announces that it has received a patent from the U.S. Patent and Trademark Office for its Uttrocide-B molecule.

• Q BioMed, Inc. CEO Discusses Recently Announced International Market Authorizations and Expansion

  9/22/2020

  SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid treatment of metastatic cancer in the bone. Corin added context and his insights into the other Company news regarding the GMP production contract has been init

• Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and Europe

  9/15/2020

  Several International Market Authorisations Expected in Q4 Expanding Access to South and Central America and Asia

• Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program

  8/26/2020

  Proof of concept would validate platform for multiple indications and therapeutic alternatives in infectious diseases and others

• Q Biomed to Scale up Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer, in Preparation for IND Filing

  7/22/2020

  Q BioMed continues its collaboration with Chemveda Life Sciences to prepare for pre-clinical evaluation, Orphan Drug filing and Investigational New Drug (IND) filing of Uttroside-B Novel Therapeutic Shows Remarkable Efficacy in HepG2 Cell Lines NEW YORK , July 22, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very pleased to contin

• Q BioMed, Inc. CEO Discusses Recently Announced Global Distribution Partnership with Caligor Coghlan Pharma Services in Audio Interview with SmallCapVoice.com

  7/9/2020

  SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses the development of the Company’s exclusive Named Patient Program distribution agreement for its non-opioid metastatic cancer bone pain drug, Strontium89, with Caligor Coghlan Pharma Services (CCPS) for the ex-U.S. market

• Q BioMed Announces Global Distribution Partnership With Caligor Coghlan Pharma Services for its Non-Opioid Cancer Palliation Drug

  7/8/2020

  Caligor Coghlan Pharma Services to Distribute Strontium89 (Strontium Chloride Injection Sr-89 USP) Outside the United States Agreement opens international markets ahead of schedule under Named Patient Program

• Q BioMed Updates Shareholders

  6/30/2020

  - Strontium89 launched; contract manufacturer now producing commercial scale quantities; sales revenue expected to be booked this quarter - $25 million in annual sales anticipated in 2022 based on the current potential market size - COVID-19 Investigational New Drug application (or similar clinical trial proposal) to regulators planned for late 2020   [30-June-2020]  

• QBioMed to Support and Exhibit at Living Beyond Breast Cancer 2020 Virtual Conference on June 13-14, 2020

  6/12/2020

  Q BioMed (OTC: QBIO) is proud to be a Supporter of the Living Beyond Breast Cancer (LBBC) 2020 Virtual Conference on Metastatic Breast Cancer taking place June 13 and 14, 2020.

• Q BioMed Launches New Website Strontium89.com and Digital Marketing Campaign for Strontium89 (Strontium Chloride Sr-89 Injection, USP) Non-opioid Treatment for Metastatic Bone Pain

  5/15/2020

  - Campaign for doctors and healthcare professionals eliminates need for in-person sales rep meetings; ideally suited for current social distancing guidelines and unique challenges faced by healthcare professionals today - Several institutions considering use of Strontium89 for their patients   [15-May-2020]   NEW YORK , May 15, 2020 /PRNewswire/ --  Q BioMed In

• Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics

  4/22/2020

  Artificial Intelligence (AI) and computational biophysics will be deployed to rapidly develop drugs for COVID-19 and other viral infections based on Mannin Research's Tie2 platform in new joint venture with Cyclica

• Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a Minimum of $3,800,000 of Debt Conversion

  4/7/2020

  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the entering of a significant financial transaction with its lead investor, Yorkville Advisors Global ("YA").

• 

  BioSpace Movers & Shakers, April 3

  4/3/2020

  Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.

• Q BioMed Adds to Leadership Team With Global Head of Regulatory Affairs

  3/31/2020

  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company,  announced today the appointment of Geoff Fatzinger as the Global Head of Regulatory Affairs

• Q BioMed Expands Leadership Team With Chief Commercial Officer

  3/30/2020

  Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company,  announced today the appointment of Kristin Keller to the newly created position of Chief Commercial Officer. Kristin will be focused on driving the global

• Q BioMed Launches Non-opioid Treatment for Metastatic Bone Pain

  2/13/2020

  - First orders for product received, with initial doses to ship in February - Full commercial production and availability starting in March

• Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases

  2/4/2020

  - Preclinical data show unique platform addresses vascular leakage, which may support the health of patients during coronavirus infection

• Q BioMed Technology Partner Mannin Research Inc. Presents Data Showing Potential Treatment to Protect the Kidney in Acute Kidney Injury Using Mannin Tie2 Activator

  11/26/2019

  Data presented during "Acute Kidney Injury" symposium at the American Society for Nephrology 2019 Annual Meeting Expands Pipeline of Platform Technology

• Q BioMed Announces FDA Approval

  11/20/2019

  Q BioMed Inc. (OTCQB: QBIO),  announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture the Company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP.

• Q BioMed Announces $7.5M Grant Benefiting its Preclinical Product Development Pipeline

  11/5/2019

   Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony